Signal from the log
Altis Labs
25 M$ · Series A · Canada
Altis Labs lit les scanners déjà faits pendant un essai clinique et en tire une prédiction de survie. Son modèle IPRO vise à mesurer l'effet d'un traitement dès le début de l'essai, là où les critères d'imagerie classiques attendent des mois. Johnson & Johnson l'a testé après coup sur l'essai de phase 3 MARIPOSA.
Verified
Announced on , logged by the watch of 17 September 2026.
- Operation
- Funding round
- Announced amount
- 25 M$
- Stage
- Series A
- Country
- Canada
What the log says
Editorial note, in French
Communiqué ouvert, montant relu et fonds nommés.
The investors
Led by OrbiMed , Qiming Venture Partners USA , with Innovation Endeavors , Benchstrength , Fusion Fund , Lumira Ventures
Provenance
Source businesswire
Logged on 17 September 2026
Description Written in French during the watch run. Written during the watch run, after reading the issuer's press release or the source article.
Verification Amounts and fund names were double checked against the issuer's press release or an official filing.
What this status means
Verified The press release was opened: amount double checked, funds named. The article remains to be written.
The rule A signal is never removed from the log. A round set aside stays readable with its reason, because a collection you cannot reread is a collection you cannot correct.